

Tel. : (91 832) 2257253 / 6714444 Fax : (91 832) 2257044 E-mail : gkbophthalmics@gkb.net Website : www.gkb.net

GKB/ STK- EXCH February 14, 2023

To, The Listing Department BSE Limited Phiroze Jeejubhoy Towers, Dalal Street <u>Mumbai - 400 001</u>

Dear Sir,

Ref : Scrip Code No.: 533212

## Sub : Statement of deviation(s) or variation(s) under Regulation 32 of SEBI ( Listing Obligations and Disclosure Requirements ) Regulations , 2015

Pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019, dated December 24, 2019, we would like to inform you that the Audit Committee in their meeting held on February 14, 2023, has reviewed the utilisation of funds which were raised by means of preferential allotment and noted that there was no utilization of funds, during the quarter ended December 31, 2022.

Enclosed please find the Statement as per the format, giving details of the same.

Kindly take the information on records.

Thanking you

Yours faithfully, For GKB Ophthalmics Limited

Fichell

Pooja Bicholkar Company Secretary





Statement of Deviation / Variation in utilisation of funds raised				
Name of listed entity	GKB Ophthalmics Limited			
Mode of Fund Raising	Public Issues / Rights Issues / Preferential			
	Issues / QIP / Others			
Date of Raising Funds	July 27, 2018 and January 22, 2020			
Amount Raised	Equity Shares - Rs. 7,54,85,000			
	Warrants - Rs. 2,90,62,500			
	Warrants - Rs. 4,65,00,000 (75% of balance			
	warrant money received on or before			
	January 21, 2020, with respect to 4,00,000			
	warrants)			
Report filed for Quarter ended	December 31, 2022			
Monitoring Agency	applicable / not applicable			
Monitoring Agency Name, if applicable	<del>Yes</del> / No			
Is there a Deviation / Variation in use of funds raised	There was no utilization of funds for the			
	quarter ended December 31, 2022.			
If yes, whether the same is pursuant to change in terms of a contract				
or objects, which was approved by the shareholders				
If Yes, Date of shareholder Approval	in the			
Explanation for the Deviation / Variation				
Comments of the Audit Committee after review	The Audit Committee noted that there was			
	no utilization of funds for the quarter			
	ended December 31, 2022.			
Comments of the auditors, if any	10 M			



Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variati on for the quarter according to applicable object	Remarks, if an
The Company will utilize the funds raised through preferential issue to scale up the operations in the present business, to fund the future growth plans of the Company both organically or inorganically, also to meet long term capital requirements of the Company and other general corporate purpose.	N.A	15.10 Crores	N.A	15.05 Crores	N.A	N.A
Deviation or variation could me	ean:					
(a) Deviation in the objects or p				ikan sana ana ika sa kata sa ka		
(b) Deviation in the amount of				the second se		
(c) Change in terms of a contrac	at referred to in th	ne fund raising do	cument i.e. prosp	ectus, letter of offer	r, etc	
Si cho Uh Pooja Bicholkar Company Secretary	MAPUSA GOA					